Literature DB >> 29739616

Schistosoma egg-induced liver pathology resolution by Sm-p80-based schistosomiasis vaccine in baboons.

Loc Le1, Adebayo J Molehin2, Stewart Nash2, Souad R Sennoune2, Gul Ahmad3, Workineh Torben4, Weidong Zhang2, Afzal A Siddiqui5.   

Abstract

Schistosomiasis remains a serious chronic debilitating hepato-intestinal disease. Current control measures based on mass drug administration are inadequate due to sustained re-infection rates, low treatment coverage and emergence of drug resistance. Hence, there is an urgent need for a schistosomiasis vaccine for disease control. In this study, we assessed the anti-pathology efficacy of Schistosoma mansoni large subunit of calpain (Sm-p80)-based vaccine against schistosomiasis caused by infections with Schistosoma mansoni in baboons. We also evaluated the disease transmission-blocking potential of Sm-p80 vaccine. Immunisations with Sm-p80-based vaccine resulted in significant reduction of hepatic egg load in vaccinated baboons (67.7% reduction, p = 0.0032) when compared to the control animals, indicative of reduction in pathology. There was also a significant reduction in sizes of egg-induced granulomas in baboons immunised with Sm-p80 vaccine compared to their control counterparts. Egg hatching rate analysis revealed an overall 85.6% reduction (p = 0.0018) in vaccinated animals compared to the controls, highlighting the potential role of Sm-p80 vaccine in disease transmission. The findings on anti-pathology efficacy and transmission-blocking potential presented in this study have formed the basis for a large-scale double-blinded baboon experiment that is currently underway.
Copyright © 2018 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anti-pathology; Schistosoma mansoni; Schistosomiasis; Sm-p80 vaccine

Mesh:

Substances:

Year:  2018        PMID: 29739616     DOI: 10.1016/j.pathol.2018.01.004

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  3 in total

1.  Single oral fixed-dose praziquantel-miltefosine nanocombination for effective control of experimental schistosomiasis mansoni.

Authors:  Maha M Eissa; Mervat Z El-Azzouni; Labiba K El-Khordagui; Amany Abdel Bary; Riham M El-Moslemany; Sara A Abdel Salam
Journal:  Parasit Vectors       Date:  2020-09-15       Impact factor: 3.876

2.  Adjuvanted Schistosoma mansoni-Cathepsin B With Sulfated Lactosyl Archaeol Archaeosomes or AddaVax™ Provides Protection in a Pre-Clinical Schistosomiasis Model.

Authors:  Dilhan J Perera; Adam S Hassan; Yimei Jia; Alessandra Ricciardi; Michael J McCluskie; Risini D Weeratna; Momar Ndao
Journal:  Front Immunol       Date:  2020-11-16       Impact factor: 7.561

3.  Schistosoma mansoni Larval Extracellular Vesicle protein 1 (SmLEV1) is an immunogenic antigen found in EVs released from pre-acetabular glands of invading cercariae.

Authors:  Thomas A Gasan; Marije E Kuipers; Grisial H Roberts; Gilda Padalino; Josephine E Forde-Thomas; Shona Wilson; Jakub Wawrzyniak; Edridah M Tukahebwa; Karl F Hoffmann; Iain W Chalmers
Journal:  PLoS Negl Trop Dis       Date:  2021-11-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.